Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial

References

• Vernon G , Baranova A , Younossi Z . Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. https://doi.org/10.1111/j.1365–2036.2011.04724.x. Cited in: PubMed; PMID:21623852.
   PubMed Web of Science ®Google Scholar
• Chalasani N , Younossi Z , Lavine JE , Diehl AM , Brunt EM , Cusi K , Charlton M , Sanyal AJ . The diagnosis and management of non‐alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. https://doi.org/10.1002/hep.25762. Cited in: PubMed; PMID:22488764.
   PubMed Web of Science ®Google Scholar
• Hassan K , Bhalla V , El Regal ME , A-Kader HH . Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20:12082. https://doi.org/10.3748/wjg.v20.i34.12082. Cited in: PubMed; PMID:25232245.
   PubMed Web of Science ®Google Scholar
• Lankarani KB , Ghaffarpasand F , Mahmoodi M , Lotfi M , Zamiri N , Heydari ST , Fallahzadeh MK , Maharlouei N , Babaeinejad M , Mehravar S . Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013;13.
   Web of Science ®Google Scholar
• Younossi Z . Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28:2–12. https://doi.org/10.1111/j.1365–2036.2008.03710.x. Cited in: PubMed; PMID:18410557.
   PubMed Web of Science ®Google Scholar
• Gossard A , Lindor K . Current therapies for nonalcoholic fatty liver disease. Drugs Today (Barcelona, Spain: 1998). 2011;47:915–922. https://doi.org/10.1358/dot.2011.47.12.1688530.
   PubMed Web of Science ®Google Scholar
• Harrison SA , Day CP . Benefits of lifestyle modification in NAFLD. Gut. 2007;56:1760–1769. https://doi.org/10.1136/gut.2006.112094. Cited in: PubMed; PMID:17911352.
   PubMed Web of Science ®Google Scholar
• Lam YY , Peterson CM , Ravussin E . Resveratrol vs. calorie restriction: data from rodents to humans. Exp Gerontol. 2013;48:1018–1024.
   Google Scholar
• Dali‐Youcef N , Lagouge M , Froelich S , Koehl C , Schoonjans K , Auwerx J . Sirtuins: the ‘magnificent seven’, function, metabolism and longevity. Ann Med. 2007;39:335–345. https://doi.org/10.1080/07853890701408194. Cited in: PubMed; PMID:17701476.
   PubMed Web of Science ®Google Scholar
• Wang Y . Molecular links between caloric restriction and Sir2/SIRT1 activation. Diabetes Metab J. 2014;38:321–329. https://doi.org/10.4093/dmj.2014.38.5.321. Cited in: PubMed; PMID:25349818.
   PubMedGoogle Scholar
• Kelly GS . A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev: a journal of clinical therapeutic. 2010;15:313–328.
   PubMed Web of Science ®Google Scholar
• Kelly G . A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. Altern Med Rev. 2010;15:245–63. Cited in: PubMed; PMID:21155626.
   PubMed Web of Science ®Google Scholar
• Colak Y , Ozturk O , Senates E , Tuncer I , Yorulmaz E , Adali G , Doganay L , Enc FY . SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit Basic Res. 2011;17:HY5–HY9.
   Google Scholar
• Nogueiras R , Habegger KM , Chaudhary N , Finan B , Banks AS , Dietrich MO , Horvath TL , Sinclair DA , Pfluger PT , Tschöp MH . Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012;92:1479–1514. https://doi.org/10.1152/physrev.00022.2011. Cited in: PubMed; PMID:22811431.
   PubMed Web of Science ®Google Scholar
• Cohen HY , Miller C , Bitterman KJ , Wall NR , Hekking B , Kessler B , Howitz KT , Gorospe M , de Cabo R , Sinclair DA . Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004;305:390–392. https://doi.org/10.1126/science.1099196. Cited in: PubMed; PMID:15205477.
   PubMed Web of Science ®Google Scholar
• Civitarese AE , Carling S , Heilbronn LK , Hulver MH , Ukropcova B , Deutsch WA , Smith SR , Ravussin E . Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med. 2007;4:e76. https://doi.org/10.1371/journal.pmed.0040076. Cited in: PubMed; PMID:17341128.
   PubMed Web of Science ®Google Scholar
• Mariani S , Fiore D , Basciani S , Persichetti A , Contini S , Lubrano C , Salvatori L , Lenzi A , Gnessi L . Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine. 2014:1–6.
   Google Scholar
• Tauriainen E , Luostarinen M , Martonen E , Finckenberg P , Kovalainen M , Huotari A , Herzig K-H , Lecklin A , Mervaala E . Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation. J Nutr Metab. 2011 ;2011. https://doi.org/10.1155/2011/525094. Cited in: PubMed; PMID:21977315.
   PubMedGoogle Scholar
• Timmers S , Konings E , Bilet L , Houtkooper RH , van de Weijer T , Goossens GH , Hoeks J , van der Krieken S , Ryu D , Kersten S . Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612–622. https://doi.org/10.1016/j.cmet.2011.10.002. Cited in: PubMed; PMID:22055504.
   PubMed Web of Science ®Google Scholar
• Baur JA . Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev. 2010;131:261–269. https://doi.org/10.1016/j.mad.2010.02.007. Cited in: PubMed; PMID:20219519.
   PubMed Web of Science ®Google Scholar
• Howitz KT , Bitterman KJ , Cohen HY , Lamming DW , Lavu S , Wood JG , Zipkin RE , Chung P , Kisielewski A , Zhang L-L . Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191–196. https://doi.org/10.1038/nature01960. Cited in: PubMed; PMID:12939617.
   PubMed Web of Science ®Google Scholar
• Pan MH , Lai CS , Tsai ML , Ho CT . Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Mol Nutr Food Res. 2014;58:147–171. https://doi.org/10.1002/mnfr.201300522. Cited in: PubMed; PMID:24302567.
   PubMed Web of Science ®Google Scholar
• Eslamparast T , Eghtesad S , Poustchi H , Hekmatdoost A . Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 2015;7:204. https://doi.org/10.4254/wjh.v7.i2.204. Cited in: PubMed; PMID:25729475.
   PubMedGoogle Scholar
• Timmers S , Hesselink MK , Schrauwen P . Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann N Y Acad Sci. 2013;1290:83–89. https://doi.org/10.1111/nyas.12185. Cited in: PubMed; PMID:23855469.
   PubMed Web of Science ®Google Scholar
• Kim S , Jin Y , Choi Y , Park T . Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol. 2011;81:1343–1351. https://doi.org/10.1016/j.bcp.2011.03.012. Cited in: PubMed; PMID:21439945.
   PubMed Web of Science ®Google Scholar
• Shang J , Chen L-l , Xiao F-x , Sun H , Ding H-c , Xiao H . Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin. 2008;29:698–706. https://doi.org/10.1111/j.1745–7254.2008.00807.x. Cited in: PubMed; PMID:18501116.
   PubMed Web of Science ®Google Scholar
• Rivera L , Morón R , Zarzuelo A , Galisteo M . Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol. 2009;77:1053–1063. https://doi.org/10.1016/j.bcp.2008.11.027. Cited in: PubMed; PMID:19100718.
   PubMed Web of Science ®Google Scholar
• Aguirre L , Portillo MP , Hijona E , Bujanda L . Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol. 2014;20:7366. https://doi.org/10.3748/wjg.v20.i23.7366. Cited in: PubMed; PMID:24966607.
   PubMed Web of Science ®Google Scholar
• Heebøll S , Thomsen KL , Pedersen SB , Vilstrup H , George J , Grønbæk H . Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol 2014;6:188. https://doi.org/10.4254/wjh.v6.i4.188. Cited in: PubMed; PMID:24799987.
   PubMedGoogle Scholar
• Chung S , Yao H , Caito S , Hwang JW , Arunachalam G , Rahman I. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Bioph. 2010;501:79–90. https://doi.org/10.1016/j.abb.2010.05.003.
   PubMed Web of Science ®Google Scholar
• Choi Y-J , Suh H-R , Yoon Y , Lee K-J , Kim DG , Kim S , Lee B-H . Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Arch Pharm Res. 2014;37:1169–1176. https://doi.org/10.1007/s12272–014–0347-z. Cited in: PubMed; PMID:24633463.
   PubMed Web of Science ®Google Scholar
• Baur JA , Pearson KJ , Price NL , Jamieson HA , Lerin C , Kalra A , Prabhu VV , Allard JS , Lopez-Lluch G , Lewis K . Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337–342. https://doi.org/10.1038/nature05354. Cited in: PubMed; PMID:17086191.
   PubMed Web of Science ®Google Scholar
• Moghaddam MHB , Aghdam FB , Jafarabadi MA , Allahverdipour H , Nikookheslat SD , Safarpour S . The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci. 2012;18:1073–1080.
   Google Scholar
• Thomas EL , Brynes AE , Hamilton G , Patel N , Spong A , Goldin RD , Frost G , Bell JD , Taylor-Robinson SD . Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol. 2006;12:5813. https://doi.org/10.3748/wjg.v12.i36.5813. Cited in: PubMed; PMID:17007047.
   PubMed Web of Science ®Google Scholar
• Ghaemi A , Taleban FA , Hekmatdoost A , Rafiei A , Hosseini V , Amiri Z , Homayounfar R , Fakheri H . How much weight loss is effective on nonalcoholic fatty liver disease? Hepat Mon. 2013;13. https://doi.org/10.5812/hepatmon.15227. Cited in: PubMed; PMID:24358045.
   PubMed Web of Science ®Google Scholar
• Arefhosseini SR , Ebrahimi-Mameghani M , Naeimi AF , Khoshbaten M , Rashid J . Lifestyle modification through dietary intervention: health promotion of patients with non-alcoholic fatty liver disease. Health Promot Perspect. 2011;1:147. Cited in: PubMed; PMID:24688911.
   PubMedGoogle Scholar
• Ekstedt M , Franzén LE , Mathiesen UL , Thorelius L , Holmqvist M , Bodemar G , Kechagias S . Long‐term follow‐up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873. https://doi.org/10.1002/hep.21327. Cited in: PubMed; PMID:17006923.
   PubMed Web of Science ®Google Scholar
• Clark JM . Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006;40:S39–S43. Cited in: PubMed; PMID:16540766.
   PubMed Web of Science ®Google Scholar
• Yamamoto M , Iwasa M , Iwata K , Kaito M , Sugimoto R , Urawa N , Mifuji R , Konishi M , Kobayashi Y , Adachi Y . Restriction of dietary calories, fat and iron improves non‐alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007;22:498–503. https://doi.org/10.1111/j.1440–1746.2006.04548.x. Cited in: PubMed; PMID:17376040.
   PubMed Web of Science ®Google Scholar
• Méndez-del Villar M , González-Ortiz M , Martínez-Abundis E , Pérez-Rubio KG , Lizárraga-Valdez R . Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12:497–501. https://doi.org/10.1089/met.2014.0082. Cited in: PubMed; PMID:25137036.
   PubMed Web of Science ®Google Scholar
• Lagouge M , Argmann C , Gerhart-Hines Z , Meziane H , Lerin C , Daussin F , Messadeq N , Milne J , Lambert P , Elliott P . Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127:1109–1122. https://doi.org/10.1016/j.cell.2006.11.013. Cited in: PubMed; PMID:17112576.
   PubMed Web of Science ®Google Scholar
• Qiao Y , Sun J , Xia S , Tang X , Shi Y , Le G . Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct. 2014;5:1241–1249. https://doi.org/10.1039/c3fo60630a. Cited in: PubMed; PMID:24722352.
   PubMed Web of Science ®Google Scholar
• Chang C-C , Lin K-Y , Peng K-Y , Day Y-J , Hung L-M . Resveratrol exerts anti-obesity effects in high-fat diet obese mice and displays differential dosage effects on cytotoxicity, differentiation, and lipolysis in 3T3-L1 cells. Endocr J. 2016;63:169–178. https://doi.org/10.1507/endocrj.EJ15–0545. Cited in: PubMed; PMID:24722352.
   PubMed Web of Science ®Google Scholar
• Szkudelski T , Szkudelska K . Anti‐diabetic effects of resveratrol. Ann N Y Acad Sci. 2011;1215:34–39. https://doi.org/10.1111/j.1749–6632.2010.05844.x. Cited in: PubMed; PMID:21261639.
   PubMed Web of Science ®Google Scholar
• Fischer-Posovszky P , Kukulus V , Tews D , Unterkircher T , Debatin K-M , Fulda S , Wabitsch M . Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr. 2010;92:5–15. https://doi.org/10.3945/ajcn.2009.28435. Cited in: PubMed; PMID:20463039.
   PubMed Web of Science ®Google Scholar
• Price NL , Gomes AP , Ling AJ , Duarte FV , Martin-Montalvo A , North BJ , Agarwal B , Ye L , Ramadori G , Teodoro JS . SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15:675–690. https://doi.org/10.1016/j.cmet.2012.04.003. Cited in: PubMed; PMID:22560220.
   PubMed Web of Science ®Google Scholar
• Dal-Pan A , Blanc S , Aujard F . Resveratrol activates energy metabolism by influencing body temperature, locomotor activity and resting metabolic rate in a non-human primate. Comp Biochem Physiol A Mol Integr Physiol. 2009;153:S147. https://doi.org/10.1016/j.cbpa.2009.04.282.
   Google Scholar
• Wang S , Moustaid-Moussa N , Chen L , Mo H , Shastri A , Su R , Bapat P , Kwun I , Shen C-L . Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014;25:1–18. https://doi.org/10.1016/j.jnutbio.2013.09.001. Cited in: PubMed; PMID:24314860.
   PubMed Web of Science ®Google Scholar
• Yoshino J , Conte C , Fontana L , Mittendorfer B , Imai S-I , Schechtman KB , Gu C , Kunz I , Fanelli FR , Patterson BW . Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012;16:658–664. https://doi.org/10.1016/j.cmet.2012.09.015. Cited in: PubMed; PMID:23102619.
   PubMed Web of Science ®Google Scholar
• Poulsen MM , Vestergaard PF , Clasen BF , Radko Y , Christensen LP , Stødkilde-Jørgensen H , Møller N , Jessen N , Pedersen SB , Jørgensen JOL . High-dose resveratrol supplementation in obese men an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186–95. https://doi.org/10.2337/db12–0975. Cited in: PubMed; PMID:23193181.
   PubMed Web of Science ®Google Scholar
• Tiikkainen M , Bergholm R , Vehkavaara S , Rissanen A , Häkkinen A-M , Tamminen M , Teramo K , Yki-Järvinen H . Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes. 2003;52:701–707. https://doi.org/10.2337/diabetes.52.3.701. Cited in: PubMed; PMID:12606511.
   PubMed Web of Science ®Google Scholar
• Hickman I , Clouston A , Macdonald G , Purdie D , Prins   , Ash S , Jonsson J , Powell E . Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51:89–94. https://doi.org/10.1136/gut.51.1.89. Cited in: PubMed; PMID:12077098.
   PubMed Web of Science ®Google Scholar
• Huang MA , Greenson JK , Chao C , Anderson L , Peterman D , Jacobson J , Emick D , Lok AS , Conjeevaram HS . One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100:1072–1081. https://doi.org/10.1111/j.1572–0241.2005.41334.x. Cited in: PubMed; PMID:15842581.
   PubMed Web of Science ®Google Scholar
• Gómez-Zorita S , Fernández-Quintela A , Macarulla M , Aguirre L , Hijona E , Bujanda L , Milagro F , Martínez J , Portillo M . Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr. 2012;107:202–210. https://doi.org/10.1017/S0007114511002753. Cited in: PubMed; PMID:21733326.
   PubMed Web of Science ®Google Scholar
• Shiozaki M , Hayakawa N , Shibata M , Koike M , Uchiyama Y , Gotow T . Closer association of mitochondria with lipid droplets in hepatocytes and activation of Kupffer cells in resveratrol-treated senescence-accelerated mice. Histochem Cell Biol. 2011;136:475. https://doi.org/10.1007/s00418–011–0847–6. Cited in: PubMed; PMID:21818579.
   PubMed Web of Science ®Google Scholar
• Chen S , Zhao X , Ran L , Wan J , Wang X , Qin Y , Shu F , Gao Y , Yuan L , Zhang Q . Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis. 2015;47:226–232. https://doi.org/10.1016/j.dld.2014.11.015. Cited in: PubMed; PMID:25577300.
   PubMedGoogle Scholar
• Chachay VS , Macdonald GA , Martin JH , Whitehead JP , O'Moore-Sullivan TM , Lee P , Franklin M , Klein K , Taylor PJ , Ferguson M . Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092–2103. e2096. https://doi.org/10.1016/j.cgh.2014.02.024. Cited in: PubMed; PMID:24582567.
   PubMed Web of Science ®Google Scholar
• Faghihzadeh F , Adibi P , Rafiei R , Hekmatdoost A . Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34:837–843. https://doi.org/10.1016/j.nutres.2014.09.005. Cited in: PubMed; PMID:25311610.
   PubMed Web of Science ®Google Scholar
• Heebøll S , Kreuzfeldt M , Hamilton-Dutoit S , Kjær Poulsen M , Stødkilde-Jørgensen H , Møller HJ , Jessen N , Thorsen K , Kristina Hellberg Y , Bønløkke Pedersen S . Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51:456–464. https://doi.org/10.3109/00365521.2015.1107620. Cited in: PubMed; PMID:26784973.
   PubMed Web of Science ®Google Scholar
• Conlon BA , Beasley JM , Aebersold K , Jhangiani SS , Wylie-Rosett J . Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients. 2013;5:4093–4114. https://doi.org/10.3390/nu5104093. Cited in: PubMed; PMID:24152749.
   PubMed Web of Science ®Google Scholar
• Promrat K , Kleiner DE , Niemeier HM , Jackvony E , Kearns M , Wands JR , Fava JL , Wing RR . Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121–129. https://doi.org/10.1002/hep.23276. Cited in: PubMed; PMID:19827166.
   PubMed Web of Science ®Google Scholar
• Faghihzadeh F , Adibi P , Hekmatdoost A . The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796–803. https://doi.org/10.1017/S0007114515002433. Cited in: PubMed; PMID:26234526.
   PubMed Web of Science ®Google Scholar
• Barger JL , Kayo T , Vann JM , Arias EB , Wang J , Hacker TA , Wang Y , Raederstorff D , Morrow JD , Leeuwenburgh C . A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PloS One. 2008;3:e2264. https://doi.org/10.1371/journal.pone.0002264. Cited in: PubMed; PMID:18523577.
   PubMed Web of Science ®Google Scholar
• Bhatt JK , Thomas S , Nanjan MJ . Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32:537–541. https://doi.org/10.1016/j.nutres.2012.06.003. Cited in: PubMed; PMID:22901562.
   PubMed Web of Science ®Google Scholar
• Brasnyó P , Molnár GA , Mohás M , Markó L , Laczy B , Cseh J , Mikolás E , Szijártó IA , Mérei A , Halmai R . Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106:383–389. https://doi.org/10.1017/S0007114511000316. Cited in: PubMed; PMID:21385509.
   PubMed Web of Science ®Google Scholar
• Movahed A , Nabipour I , Lieben Louis X , Thandapilly SJ , Yu L , Kalantarhormozi M , Rekabpour SJ , Netticadan T . Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013;2013:851267. https://doi.org/10.1155/2013/851267.
   PubMed Web of Science ®Google Scholar
• Chatrath H , Vuppalanchi R , Chalasani N . Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32(1):22–29. Cited in: PubMed; PMID:22418885.
   PubMed Web of Science ®Google Scholar
• Lang H-F , Chou C-Y , Sheu WH-H , Lin J-Y . Weight loss increased serum adiponectin but decreased lipid levels in obese subjects whose body mass index was lower than 30 kg/m2 . Nutr Res. 2011;31:378–386. https://doi.org/10.1016/j.nutres.2011.04.004. Cited in: PubMed; PMID:21636016.
   PubMed Web of Science ®Google Scholar
• Kumar BJ , Joghee NM . Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. Int J Pharm. 2013;4:245–249. https://doi.org/10.7897/2230–8407.04849.
   Google Scholar
• Jiang WJ . Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun. 2008;373:341–344. https://doi.org/10.1016/j.bbrc.2008.06.048. Cited in: PubMed; PMID:18577374.
   PubMed Web of Science ®Google Scholar
• Guarente L . Calorie restriction and sirtuins revisited. Genes Dev. 2013;27:2072–2085. https://doi.org/10.1101/gad.227439.113. Cited in: PubMed; PMID:24115767.
   PubMed Web of Science ®Google Scholar
• Chen LL , Deng XQ , Li NX . [Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats]. Zhonghua Yi Xue Za Zhi. 2007;87:1434–1437. Cited in: PubMed; PMID:17785073.
   PubMedGoogle Scholar
• Engin-Ustun Y , Caglayan EK , Kara M , Gocmen AY , Polat MF , Aktulay A . The effect of Ramadan fasting on sirtuin and visfatin levels. Interv Med Appl Sci. 2016;8:14–19. Cited in: PubMed; PMID:28250976.
   PubMedGoogle Scholar
• Colak Y , Yesil A , Mutlu HH , Caklili OT , Ulasoglu C , Senates E , Takir M , Kostek O , Yilmaz Y , Enc FY . A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. J Gastrointest Liver Dis. 2014;23:311–319.
   PubMed Web of Science ®Google Scholar
• Ajmo JM , Liang X , Rogers CQ , Pennock B , You M . Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol. 2008;295:G833–G842. https://doi.org/10.1152/ajpgi.90358.2008. Cited in: PubMed; PMID:18755807.
   PubMed Web of Science ®Google Scholar
• Friedewald WT , Levy RI , Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
   PubMed Web of Science ®Google Scholar